Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Excluded: EGFR sensitizing mutation

Participants with sensitising EGFR mutations

Excluded: ALK translocation

Participants with ... ALK translocations

Excluded: PD-L1 (CD274) expression <1%

Participants with baseline PD-L1 expression status <1% (Arms 6 and 7 only)

Cannot have received: immune-mediated therapy (anti-CTLA-4, anti-TIGIT, anti-PD-1, anti-PD-L1, anti-PD-L2, agents targeting the adenosine pathway, anti-NKG2A, anti-HLA-E agents, anti-LIF agents, TROP2 targeting ADC, ADC containing a chemotherapy agent that inhibits TOP1 activity)

Prior exposure to approved or investigational immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains), anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies. Participants who received agents targeting the adenosine pathway, anti-NKG2A, anti-HLA-E agents, and anti-LIF agents are also excluded. Participants who have received previous treatment with a TROP2 targeting ADC or with another ADC containing a chemotherapy agent that inhibits TOP1 activity are also excluded.

Cannot have received: preoperative radiotherapy

Participants who have preoperative radiotherapy treatment as part of their care plan

Cannot have received: concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment

Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment